3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Kilpest India — Investor Presentation (November 2020)
34 slides from 3b Blackbio Dx's investor presentation, Nov 5, 2020
Slide 1: Cover letter to Bombay Stock Exchange
November 5, 2020 The Relationship Manager, Department of Corporate Relations Bombay Stock Exchange Ltd (BSE), P.J. Towers, Dalal Street Fort, MUMBAI – 400 001 Dear Sir/Madam, Please find the enclosed herewith Investor’s Presentation / Company Update of Agrochemicals and Diagnostic Kits (Health Care)
Slide 2: Investor Presentation Nov 2020
Farmer’s Trusted Agro-Input Partner for 48 Years Reliable and Affordable Healthcare Diagnostic Solutions INVESTOR PRESENTATION Nov’ 2020
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the ‚Presentation‛), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the ‚Company‛), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation t
Slide 4: Kilpest Existing Products
Kilpest Existing Products Chemicals Biologicals No. of Products No. of Products “ Insecticides 70 “ Bio pesticide 07 “ Antibacterials 01 “ Bio fungicide 01 “ Fungicides 15 “ Bio fertilizers 05 “ Herbicides 11 “ Bio nematicides 01 “ Public Health 11 “ Public Health 02 “ Microfertilizers 02 “ Health &
Slide 5: Business Overview and Strengths
Business Overview and Strengths Experienced team & state of the art facility located in the center of India - with GST implementation this should give a boost to the company “ 48 yrs old Pesticide Formulation Company, well established in central India, strong brand equity in central India especially
Slide 6: Financial Performance: Key Highlights
Financial Performance : Key Highlights KILPEST (Consolidated) Q2F21 Q2 FY20 11227.6 1065.18% 7977.42 2772.47% Net sales 11227.60 963.59 Q2F21 Profit before tax 7977.42 277.72 Q2F20 Profit after tax 5973.25 225.03 963.59 277.72 Paid up Equity share capital 750.81 750.81 Revenue PBT Reserves 1636.39 1
Slide 7: Present Market Overview/Outlook
Present Market Overview/Outlook • Sales during the first half remains static due to COVID-19 Lockdown • Company will continue to focus on Public Health/warehousing sector and exports. As due to COVID-19, Private agriculture market is uncertain Detailed Presentation for the subsidiary follows:
Slide 8: From the house of Kilpest India Ltd.
Since 1972 From the house of Kilpest India Limited, KILPEST INDIA LTD. India’s most trusted agro-chemical brand proudly brings First licensed Molecular Diagnostics (IVD) manufacturing facility in India under Medical Device Rule 2017 ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GEN
Slide 9: From the house of KILPEST India Ltd.
From the house of KILPEST India Ltd. 3B BlackBio Biotech India Limited has become India’s leading healthcare company specialized in the development of molecular biology fine-chemicals as tools for diagnostic/ pathology segment of healthcare. The Company is CDSCO Licensed, ISO 13485:2016 certified, G
Slide 10: TRUPCR from 3B BlackBio Biotech: Vision and Mission
TRUPCR® from 3B BlackBio Biotech (I) Ltd. Vision Reliable and affordable healthcare solutions for all Mission 3B BlackBio Biotech (I) Ltd. with its TRUPCR® brand of products is committed to design and develop molecular diagnostics products of superior quality and value that continuously improves the
Slide 11: Timeline & Milestones
Timeline & Milestones more than ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 12: Growth Canvas
Growth Canvas ₹15,750.00 300 H1 2021 ₹15,750.00 300 ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 13: Financial Highlights Q2-FY21
Financial Highlights Q2-FY21 10733.4 7844.29 2753.41% 3194.95% 376.16 238.07 Revenue EBITDA 5860.08 7837.29 3299.00% 3144.42% Q2FY21 Q2FY20 230.57 180.62 PBT PAT Rs. In Lakhs. ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 14: Events related to COVID-19
Events related to COVID -19 1. The company got approval from ICMR on 2nd April, 2020 and license from CDSCO on 4th April, 2020 for selling RT-PCR Kit for COVID-19, under its brand name TRUPCR® SARS-CoV-2 RT qPCR Kit (Real-Time PCR based detection of SARS-CoV-2 virus) Version 2.0, This test comes wit
Slide 15: Our Beneficiaries
Our Beneficiaries FOR PATIENTS FOR LABORATORIES CLINICALLY VALIDATED PRECISE TRUPCR® kits are calibrated to WHO standards and TRUPCR® offers highly sensitive and precise qPCR assays as clinically validated on wide variety and numbers of samples. indicated by minimum variability of replicates and mul
Slide 16: Work Process
Work Process PLAN RESEARCH Feasibility DESIGN DEVELOP VALIDATIONS APPROVALS COMMERCIALIZATION (Technical & Commercial) IMPROVEMENT SUPPORT ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 17: R&D People and Laboratory Infrastructure
R&D R&D People • Highly educated team of scientist from varied backgrounds • Dedicated teams for respective segments • Separate onco team headed by researchers (Ph.Ds.) from oncology background • Separate team for infectious parameters headed by researchers (Ph.Ds.) from infectious diseases backgrou
Slide 18: Product QC - Our Strength
Product QC - Our Strength All TRUPCR® products are passed through stringent QC protocols to ensure optimal performance at customer site “ QC of raw material “ QC of every final lot “ Cherrypicked QC of final batch Besides above routine QC practices, Kits are QC checked on respective* real-time cycle
Slide 19: Our Certificates
Our Certificates US FDA EUA COVID-19 RT-PCR Kit CDSCO Licensed Diagnostic Kits ISO 13485:2016 Certified Company ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 20: Technology Focus
Technology Focus High Volume Cytogenetics Real-Time PCR 3B’s Focus Low Growth High Growth Other Molecular Techniques Sanger Sequencing Next Generation Mass Spec Hybridization Sequencing Microarray Low Volume ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 21: Molecular Diagnostics
Molecular Diagnostics “ The process of identifying a disease by studyingONCOLOGY molecules, such as proteins, DNA, and RNA, in a tissue or fluid. “ Molecular diagnostics is a technique used to analyze biological markers in the genome and proteome„the individual’s genetic code and how their cells exp
Slide 22: Molecular diagnostics market source
Source-https://www.gminsights.com/pressrelease/molecular-diagnostics-market-size
Slide 23: Product Segments
Product Segments ONCOLOGY ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 24: All Inclusive TRUPCR Products
All Inclusive TRUPCR® Products TRUPCR range of products offers end-to-end standardized solutions from samples to optimized end-results Nucleic Acid Detection Sample NucleicAcid Nucleic Acid Extraction & and Analysis Management Preparation Amplification Purification TRUPCR Nucleic Acid Extraction kit
Slide 25: Next Generation Sequencing
Next Generation Sequencing Launching soon… Next Generation Sequencing Assays Real image of NGS facility at 3B BlackBio Biotech (I) Ltd. Bhopal, India ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 26: Our National Presence
Our National Presence ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 27: Going Global
Going Global ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 28: New Products Launched in H1 2020-21
New Products Launched in H1 2020-21 TRUPCR® PIK3CA Mutation Kit Qualitative Detection of PIK3CA Mutations on real-time PCR TRUPCR® IDH1/2 Detection Kit Detection of IDH1 and IDH2 mutations using real-time PCR TRUPCR® SARS-CoV-2 RT qPCR Kit (Version 2.0) & (Version 3.2) Detection of SARS-CoV-2 virus
Slide 29: Global Recognition
Global Recognition ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 30: Contractual Business and Tender Business
Contractual Business • We are happy to inform that the Company to ensure long term assured business, has started signing long term (2-3 yr) contract with large customers. • As on date the company has seven contracts running out of which 1 has been executed in this quarter which ensures yearly busine
Slide 31: Growth Drivers
Growth Drivers “ Improvement in Indian healthcare industry with high demand in medicaltourism “ Increasing number of molecular tests being introduced by labs External Growth “ Evolution of disease profiles. New viruses and cancers are been diagnosed Drivers “ Increase in evidence-based treatments /
Slide 32: National MSME Award 2018
National MSME Award- 2018 by Hon'ble President of India, Shri Ram Nath Kovind. Hon'ble President of India, Shri Ram Nath Kovind on Friday on the occasion of 20th National Technology Day presented the national award for successful commercialization of indigenous technology at Vigyan Bhavan, New Delhi
Slide 33: Outstanding Achievement Award for Excellence in R&D
Outstanding Achievement Award for Excellence in R&D by FMPCCI, Bhopal. 3B BLACKBIO BIOTECH (I) LTD. Bhopal is awarded with the ‘Outstanding Achievement Award in recognition of excellence in R&D through technology in MSME enterprise category’, during the 4th Outstanding Achievement Award 2016, held o
Slide 34: JAI HIND
JAI HIND ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Kilpest India — Investor Presentation (November 2020) on 6ix